214 related articles for article (PubMed ID: 32351286)
41. Uric acid induced hepatocytes lipid accumulation through regulation of miR-149-5p/FGF21 axis.
Chen S; Chen D; Yang H; Wang X; Wang J; Xu C
BMC Gastroenterol; 2020 Feb; 20(1):39. PubMed ID: 32070295
[TBL] [Abstract][Full Text] [Related]
42. Predictors of non-alcoholic fatty liver disease (NAFLD) among children with obesity.
Mohamed RZ; Jalaludin MY; Anuar Zaini A
J Pediatr Endocrinol Metab; 2020 Feb; 33(2):247-253. PubMed ID: 31926095
[TBL] [Abstract][Full Text] [Related]
43. Relationship Between Serum Uric Acid Levels and Nonalcoholic Fatty Liver Disease in Non-Obese Patients.
Oral A; Sahin T; Turker F; Kocak E
Medicina (Kaunas); 2019 Sep; 55(9):. PubMed ID: 31533345
[No Abstract] [Full Text] [Related]
44. [Correlation between serum uric acid and risk of new-onset nonalcoholic fatty liver disease: a 5-year observational cohort study].
Bai JX; Shu RM; Huang Y; Peng Z
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):271-275. PubMed ID: 29996338
[No Abstract] [Full Text] [Related]
45. Association between serum uric acid and nonalcoholic fatty liver disease in the US population.
Shih MH; Lazo M; Liu SH; Bonekamp S; Hernaez R; Clark JM
J Formos Med Assoc; 2015 Apr; 114(4):314-20. PubMed ID: 25839764
[TBL] [Abstract][Full Text] [Related]
46. Association of the Serum Uric Acid-to-Creatinine Ratio with Nonalcoholic Fatty Liver Disease Diagnosed by Computed Tomography.
Seo YB; Han AL
Metab Syndr Relat Disord; 2021 Mar; 19(2):70-75. PubMed ID: 33314991
[No Abstract] [Full Text] [Related]
47. Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD.
Lombardi R; Pisano G; Fargion S
Int J Mol Sci; 2016 Apr; 17(4):548. PubMed ID: 27077854
[TBL] [Abstract][Full Text] [Related]
48. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds.
Xu C; Wan X; Xu L; Weng H; Yan M; Miao M; Sun Y; Xu G; Dooley S; Li Y; Yu C
J Hepatol; 2015 Jun; 62(6):1412-9. PubMed ID: 25623823
[TBL] [Abstract][Full Text] [Related]
49. Insulin-like growth factor 1 and metabolic parameters are associated with nonalcoholic fatty liver disease in obese children and adolescents.
Liang S; Cheng X; Hu Y; Song R; Li G
Acta Paediatr; 2017 Feb; 106(2):298-303. PubMed ID: 27889912
[TBL] [Abstract][Full Text] [Related]
50. Serum C16:1n7/C16:0 ratio as a diagnostic marker for non-alcoholic steatohepatitis.
Yamada K; Mizukoshi E; Seike T; Horii R; Terashima T; Iida N; Kitahara M; Sunagozaka H; Arai K; Yamashita T; Honda M; Takamura T; Harada K; Kaneko S
J Gastroenterol Hepatol; 2019 Oct; 34(10):1829-1835. PubMed ID: 30864239
[TBL] [Abstract][Full Text] [Related]
51. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome.
Kargiotis K; Athyros VG; Giouleme O; Katsiki N; Katsiki E; Anagnostis P; Boutari C; Doumas M; Karagiannis A; Mikhailidis DP
World J Gastroenterol; 2015 Jul; 21(25):7860-8. PubMed ID: 26167086
[TBL] [Abstract][Full Text] [Related]
52. Uric acid in metabolic syndrome: From an innocent bystander to a central player.
Kanbay M; Jensen T; Solak Y; Le M; Roncal-Jimenez C; Rivard C; Lanaspa MA; Nakagawa T; Johnson RJ
Eur J Intern Med; 2016 Apr; 29():3-8. PubMed ID: 26703429
[TBL] [Abstract][Full Text] [Related]
53. Association of uric acid levels with components of metabolic syndrome and non-alcoholic fatty liver disease in overweight or obese children and adolescents.
Cardoso AS; Gonzaga NC; Medeiros CC; Carvalho DF
J Pediatr (Rio J); 2013; 89(4):412-8. PubMed ID: 23791233
[TBL] [Abstract][Full Text] [Related]
54. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease.
Amacher DE
Biomarkers; 2014 Nov; 19(7):541-52. PubMed ID: 25189636
[TBL] [Abstract][Full Text] [Related]
55. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
Vilar-Gomez E; Chalasani N
J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
[TBL] [Abstract][Full Text] [Related]
56. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
57. Role of Fatty Liver Index and Metabolic Factors in the Prediction of Nonalcoholic Fatty Liver Disease in a Lean Population Receiving Health Checkup.
Hsu CL; Wu FZ; Lin KH; Chen YH; Wu PC; Chen YH; Chen CS; Wang WH; Mar GY; Yu HC
Clin Transl Gastroenterol; 2019 May; 10(5):1-8. PubMed ID: 31082856
[TBL] [Abstract][Full Text] [Related]
58. High uric acid, reduced glomerular filtration rate and non-alcoholic fatty liver in young people with obesity.
Di Bonito P; Valerio G; Licenziati MR; Miraglia Del Giudice E; Baroni MG; Morandi A; Maffeis C; Campana G; Spreghini MR; Di Sessa A; Morino G; Crinò A; Chiesa C; Pacifico L; Manco M
J Endocrinol Invest; 2020 Apr; 43(4):461-468. PubMed ID: 31637675
[TBL] [Abstract][Full Text] [Related]
59. Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.
Zhang JZ; Cai JJ; Yu Y; She ZG; Li H
Gene Expr; 2019 Nov; 19(3):187-198. PubMed ID: 31010457
[TBL] [Abstract][Full Text] [Related]
60. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
